Industry Reports

Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines with already approved therapeutic proteins, announces today its revenue for the full year and last quarter of 2012. Breakdown of the operating...

In the fourth quarter of 2012, Sanofi generated sales of €8,526 million, an increase of 0.2% on a reported basis. Exchange rate movements had a positive effect of 1.9 percentage points primarily reflecting the appreciation of the U.S....

Roche delivered a strong performance in 2012, with Group sales rising 4% to 45.5 billion Swiss francs due to growing demand for its cancer medicines and increased sales of diagnostic tests to clinical laboratories. This...

AstraZeneca's revenue in the fourth quarter was down 15 percent at constant exchange rates (CER) and declined by 16 percent on an actual basis as a result of the negative impact of exchange rate movements. Loss of exclusivity...

Bristol-Myers Squibb Company has announced results for the fourth quarter of 2012 highlighted by regulatory approvals for Eliquis and Forxiga. This concluded a year in which the Company delivered growth of its key products...

Pivotal Therapeutics Inc. , a specialty pharmaceutical company with a focus on cardiovascular disease and overall health today announced its financial results and operational highlights for the quarter ended September 30, 2012. All dollar...

Plus 5 per cent growth of Hybrigenics’ operating revenues An exceptional revenue of EUR 0.96 million EUR 3.3 million raised to finance the clinical study of oral inecalcitol in chronic lymphocytic leukemia Paris, October...